Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1962 1
1966 2
1967 1
1968 1
1970 1
1971 1
1973 2
1974 1
1975 1
1976 1
1977 2
1978 1
1979 2
1980 6
1981 1
1982 5
1983 1
1985 3
1986 1
1987 2
1988 4
1989 3
1990 4
1993 1
1996 2
1997 1
1998 2
1999 2
2000 3
2001 2
2004 2
2005 6
2006 11
2007 13
2008 9
2009 11
2010 11
2011 12
2012 5
2013 9
2014 13
2015 12
2016 7
2017 8
2018 5
2019 5
2020 8
2021 8
2022 2
Text availability
Article attribute
Article type
Publication date

Search Results

193 results
Results by year
Filters applied: . Clear all
Page 1
Genetic risks of schizophrenia identified in a matched case-control study.
Oishi K, Niitsu T, Kanahara N, Sato Y, Iwayama Y, Toyota T, Hashimoto T, Sasaki T, Takase M, Shiina A, Yoshikawa T, Iyo M. Oishi K, et al. Among authors: iwayama y. Eur Arch Psychiatry Clin Neurosci. 2021 Jun;271(4):775-781. doi: 10.1007/s00406-020-01158-3. Epub 2020 Jul 4. Eur Arch Psychiatry Clin Neurosci. 2021. PMID: 32623490
A recurrent PJA1 variant in trigonocephaly and neurodevelopmental disorders.
Suzuki T, Suzuki T, Raveau M, Miyake N, Sudo G, Tsurusaki Y, Watanabe T, Sugaya Y, Tatsukawa T, Mazaki E, Shimohata A, Kushima I, Aleksic B, Shiino T, Toyota T, Iwayama Y, Nakaoka K, Ohmori I, Sasaki A, Watanabe K, Hirose S, Kaneko S, Inoue Y, Yoshikawa T, Ozaki N, Kano M, Shimoji T, Matsumoto N, Yamakawa K. Suzuki T, et al. Among authors: iwayama y. Ann Clin Transl Neurol. 2020 Jul;7(7):1117-1131. doi: 10.1002/acn3.51093. Epub 2020 Jun 12. Ann Clin Transl Neurol. 2020. PMID: 32530565 Free PMC article.
Cooperation of LIM domain-binding 2 (LDB2) with EGR in the pathogenesis of schizophrenia.
Ohnishi T, Kiyama Y, Arima-Yoshida F, Kadota M, Ichikawa T, Yamada K, Watanabe A, Ohba H, Tanaka K, Nakaya A, Horiuchi Y, Iwayama Y, Toyoshima M, Ogawa I, Shimamoto-Mitsuyama C, Maekawa M, Balan S, Arai M, Miyashita M, Toriumi K, Nozaki Y, Kurokawa R, Suzuki K, Yoshikawa A, Toyota T, Hosoya T, Okuno H, Bito H, Itokawa M, Kuraku S, Manabe T, Yoshikawa T. Ohnishi T, et al. Among authors: iwayama y. EMBO Mol Med. 2021 Apr 9;13(4):e12574. doi: 10.15252/emmm.202012574. Epub 2021 Mar 3. EMBO Mol Med. 2021. PMID: 33656268 Free PMC article.
Investigation of betaine as a novel psychotherapeutic for schizophrenia.
Ohnishi T, Balan S, Toyoshima M, Maekawa M, Ohba H, Watanabe A, Iwayama Y, Fujita Y, Tan Y, Hisano Y, Shimamoto-Mitsuyama C, Nozaki Y, Esaki K, Nagaoka A, Matsumoto J, Hino M, Mataga N, Hayashi-Takagi A, Hashimoto K, Kunii Y, Kakita A, Yabe H, Yoshikawa T. Ohnishi T, et al. Among authors: iwayama y. EBioMedicine. 2019 Jul;45:432-446. doi: 10.1016/j.ebiom.2019.05.062. Epub 2019 Jun 26. EBioMedicine. 2019. PMID: 31255657 Free PMC article.
Role of an Atypical Cadherin Gene, Cdh23 in Prepulse Inhibition, and Implication of CDH23 in Schizophrenia.
Balan S, Ohnishi T, Watanabe A, Ohba H, Iwayama Y, Toyoshima M, Hara T, Hisano Y, Miyasaka Y, Toyota T, Shimamoto-Mitsuyama C, Maekawa M, Numata S, Ohmori T, Shimogori T, Kikkawa Y, Hayashi T, Yoshikawa T. Balan S, et al. Among authors: iwayama y. Schizophr Bull. 2021 Jul 8;47(4):1190-1200. doi: 10.1093/schbul/sbab007. Schizophr Bull. 2021. PMID: 33595068 Free PMC article.
Excess hydrogen sulfide and polysulfides production underlies a schizophrenia pathophysiology.
Ide M, Ohnishi T, Toyoshima M, Balan S, Maekawa M, Shimamoto-Mitsuyama C, Iwayama Y, Ohba H, Watanabe A, Ishii T, Shibuya N, Kimura Y, Hisano Y, Murata Y, Hara T, Morikawa M, Hashimoto K, Nozaki Y, Toyota T, Wada Y, Tanaka Y, Kato T, Nishi A, Fujisawa S, Okano H, Itokawa M, Hirokawa N, Kunii Y, Kakita A, Yabe H, Iwamoto K, Meno K, Katagiri T, Dean B, Uchida K, Kimura H, Yoshikawa T. Ide M, et al. Among authors: iwayama y. EMBO Mol Med. 2019 Dec;11(12):e10695. doi: 10.15252/emmm.201910695. Epub 2019 Oct 28. EMBO Mol Med. 2019. PMID: 31657521 Free PMC article.
Peroxisome proliferator-activated receptor α as a novel therapeutic target for schizophrenia.
Wada Y, Maekawa M, Ohnishi T, Balan S, Matsuoka S, Iwamoto K, Iwayama Y, Ohba H, Watanabe A, Hisano Y, Nozaki Y, Toyota T, Shimogori T, Itokawa M, Kobayashi T, Yoshikawa T. Wada Y, et al. Among authors: iwayama y. EBioMedicine. 2020 Dec;62:103130. doi: 10.1016/j.ebiom.2020.103130. Epub 2020 Dec 2. EBioMedicine. 2020. PMID: 33279456 Free PMC article.
193 results